BCHE and early-onset autosomal dominant Alzheimer disease: Compounds inhibiting cholinesterases are considered as potential agents for the treatment of a number of diseases associated with abnormality in cholinergic neurotransmission (Alzheimer’s disease, myasthenia gravis, etc.).